99m Tc-labeled triphenylphosphonium derivative contrasting agents and molecular probes for early detection and imaging of breast tumors
US8388931B2 · kind B2 · utility
2Cited by
3References
5Claims
0Family size
Inventors
Key dates
| Filing date | Feb 27, 2009 |
| Grant date | Mar 5, 2013 |
| Priority date | — |
| Expiry date | Mar 24, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K5/1027
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
99mTc-labeled triphenylphosphonium contrasting agents that target the mitochondria and are useful for early detection of breast tumors using scintimammographic imaging. 99mTc-Mito10-MAG3 possesses advantageous radiopharmaceutical properties. The uptake in the myocardium is reduced by one to two orders of magnitude compared to 99mTc-MIBI. 99mTc-Mito10-MAG3 exhibits fast blood clearance, with a blood half-life of less than 2 minutes in rats. A diminished myocardial uptake combined with a prompt reduction of cardiovascular blood pool signal to facilitate improved signal-to-background ratios.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.